Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder - Song, J; Bergen, S E; Di Florio, A; Karlsson, R; Charney, A; Ruderfer, D M; Stahl, E A; Chambert, K D; Moran, J L; Gordon-Smith, K; Forty, L; Green, E K; et al. (Molecular psychiatry, 2016)
Keywords: 38/43; 631/208; 692/699/476/1333; Adult; Antimanic Agents - therapeutic use; Behavioral Sciences; Biochemistry & Molecular Biology; Biological Psychology; Biomarkers, Pharmacological - blood; Bipolar disorder; Bipolar Disorder - genetics; Bipolar Disorder - metabolism; brain; Care and treatment; Carrier Proteins - genetics; Carrier Proteins - metabolism; Development and progression; Female; Genetic aspects; Genetic Predisposition to Disease - genetics; Genetic Variation; Genome-wide association studies; Genome-Wide Association Study - methods; Genomes; Genomics; Genotype; Health aspects; Humans; japanese patients; Kinases; Lithium; Lithium - metabolism; Lithium - therapeutic use; Lithium Compounds - therapeutic use; maintenance treatment; Male; mechanism; Medicine; Medicine & Public Health; Methods; Middle Aged; Neurosciences; Neurosciences & Neurology; neurotrophic factor gene; Original; original-article; Pathophysiology; Pharmacotherapy; Physiology; polymorphism; Polymorphism, Single Nucleotide - genetics; prophylactic; Proteins; Psychiatry; Psykiatri; receptor potential channels; Risk Factors; schizophrenia; Self Report; Sweden; trpc5 channels; United Kingdom; New York; Sweden; United Kingdom--UK; United States--US